| abstract |
The present invention relates to amorphous Letermovir and solid oral pharmaceutical preparations containing it (immediate release drugs). This amorphous Lettermove is suitable for the preparation of immediate release preparations, if isolated from an organic solution by drying in a roller dryer specified organic solution in a volatile organic solvent, preferably in acetone, at a temperature of 30 to 60 ° C, followed by drying. or if said amorphous Lettermove is isolated by precipitation from water-miscible solvents selected from acetone or acetonitrile, by adding to excess water used as ant solvent, followed by filtration or centrifugation of the obtained amorphous Letermovir. Immediate-release formulations containing amorphous Letermovir intended for use in the prevention or treatment of diseases associated with Herpesviridae viruses, better associated with cytomegalovirus (CMV), even better associated with human cytomegalovirus (HCM) ). |